Six-month multidrug regimen being evaluated against standard treatment

Thursday, December 7, 2023 NIH Clinical Trial of Tuberculous Meningitis Drug Regimen Begins Scanning electron micrograph of Mycobacterium tuberculosis (colorized blue), the bacterium which causes TB. Credit: NIAID A NIAID-sponsored study to test a new drug regimen for tuberculous meningitis (TBM) began this week in countries where TB is prevalent, with the aim of improving treatment for people with this less common but deadly form of TB. The IMAGINE-TBM trial will compare a 6-month regimen of four drugs with the 9-month, standard-of-care regimen for TBM. IMAGINE-TBM is being implemented through the NIAID-funded Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG). National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107